Aardvark Therapeutics, Inc. (AARD)
NASDAQ · Manufacturing · Pharmaceutical preparations
$5.10−$0.4550 (−8.20%) on the dayAs of the close; data may be delayed.
AARD price, last 12 months
Key stats
- Previous close
- $5.55
- Open
- $5.57
- Day range
- $5.02 – $5.60
- 52-week range
- $3.35 – $17.94
- Volume
- 64.9K
- Avg volume (20 days)
- 133.3K
- Market cap
- $110.7M
Performance
1W−5.3%
1M−25.2%
3M+6.4%
6M+45.2%
YTD−61.2%
1Y−58.1%
vs S&P 500, 1Y−74.9 pts
Technicals and fundamentals
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $110.7M